CAMP4 Therapeutics
Stock Forecast, Prediction & Price Target
CAMP4 Therapeutics (CAMP) stock Price Target by analysts
$17.5
Potential upside: 929.41%
CAMP4 Therapeutics price prediction
What is CAMP4 Therapeutics stock analysts` prediction?
CAMP4 Therapeutics stock forecast: Based on 2 Wall Street analysts` predicted price targets for CAMP4 Therapeutics in the last 3 months, the avarage price target is $17.5, with a high forecast of $NaN. The average price target represents a 929.41% change from the last price of $1.7.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
CAMP4 Therapeutics stock Price Target by analysts
Full breakdown of analysts given CAMP4 Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Edward Tenthoff Piper Sandler | 0% 0/1 | 11 months ago | $18 958.82% upside | $9.6 | StreetInsider | Previous targets (0) |
Mani Foroohar Leerink Partners | 0% 0/1 | 11 months ago | $17 900% upside | $9.6 | StreetInsider | Previous targets (0) |
Anthony Stoss Craig-Hallum | 0% 0/1 | about 3 years ago | $10 488.23% upside | $5.8 | TheFly | Previous targets (0) |
Jerry Revich Goldman Sachs | 100% 1/1 | over 3 years ago | $5 194.11% upside | $4.93 | TheFly | Previous targets (0) |
CAMP4 Therapeutics Financial Estimates
CAMP4 Therapeutics Revenue Estimates
CAMP4 Therapeutics EBITDA Estimates
CAMP4 Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 2/28/2021 | 2/28/2022 | 2/28/2023 | 11/30/2025 | 2/28/2026 | 11/30/2026 | 2/28/2027 |
Revenue
% change YoY
| $308.58M N/A | $295.83M -4.13% | $294.94M -0.30% | Avg: $252.01M Low: $248.68M High: $254.50M avg. -14.55% | Avg: $291.96M Low: $281.61M High: $302.31M avg. 15.85% | Avg: $291.96M Low: $288.11M High: $294.85M avg. 0% | Avg: $291.96M Low: $281.61M High: $302.31M avg. 0% |
Net Income
% change YoY
| $-21.15M N/A | $-31.14M -47.22% | $-32.49M -4.30% | Avg: $35.17M Low: $34.56M High: $35.62M avg. 208.25% | Avg: $-5.78M Low: $2.00M High: $-12.89M avg. -116.43% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $0 Low: $0 High: $0 avg. 0% |
EBITDA
% change YoY
| $18.13M N/A | $7.49M -58.68% | $276K -96.31% | Avg: $12.89M Low: $12.72M High: $13.02M avg. 4573.63% | Avg: $14.94M Low: $14.41M High: $15.47M avg. 15.85% | Avg: $14.94M Low: $14.74M High: $15.09M avg. 0% | Avg: $14.94M Low: $14.41M High: $15.47M avg. 0% |
EPS
% change YoY
| -$0.62 N/A | -$0.88 -41.93% | -$0.9 -2.27% | Avg: $0.95 Low: $0.93 High: $0.96 avg. 205.55% | Avg: -$0.16 Low: $0.06 High: -$0.36 avg. -116.84% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $0 Low: $0 High: $0 avg. 0% |
Operating Expenses
% change YoY
| $125.87M N/A | $134.75M 7.05% | $129.11M -4.18% | Avg: $77.19M Low: $76.17M High: $77.95M avg. -40.20% | Avg: $89.43M Low: $86.26M High: $92.60M avg. 15.85% | Avg: $89.43M Low: $88.25M High: $90.31M avg. 0% | Avg: $89.43M Low: $86.26M High: $92.60M avg. 0% |
FAQ
What is CAMP4 Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 22.95% in 2025-2027.
We have gathered data from 1 analysts. Their low estimate is 34.56M, average is 35.17M and high is 35.62M.
What is CAMP4 Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 0.32% in 2025-2027.
We have gathered data from 1 analysts. Their low revenue estimate is $248.68M, average is $252.01M and high is $254.50M.
What is CAMP4 Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 22.17% in 2025-2027.
We have gathered data from 1 analysts. Their low earnings per share estimate is $0.93, average is $0.95 and high is $0.96.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering CAMP4 Therapeutics stock. The most successful analyst is Edward Tenthoff.